Its role in the regulation of the extracellular matrix has been thought to be critical for the development and maintenance of fibrosis, as LOXL2 inhibitors have shown benefit in liver and lung fibrosis mouse models and serum LOXL2 levels have been associated with poor prognosis in patients suffering from idiopathic pulmonary fibrosis (IPF)41–43. This evidence concerns the gene LOXL2 and idiopathic pulmonary fibrosis.